Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 4/20 | 0.65 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.65 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.65 |
| ▸ | CDC7 | O00311 | 3/20 | 0.65 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.65 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.65 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.65 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.65 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.65 |
| ▸ | IGF1R | P08069 | 1/20 | 0.65 |
| ▸ | CLK2 | P49760 | 1/20 | 0.65 |
| ▸ | GSK3A | P49840 | 1/20 | 0.65 |
| ▸ | GSK3B | P49841 | 1/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.65 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.65 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | PARP1 | P09874 | 3/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18496527 | 0.82 | PIM1 (0.70) | PIM1PIM3PIM2CDC7CSNK2A1 | |
| SCHEMBL12661345 | 0.79 | PIM1 (1.00) | PIM1PIM3PIM2CDC7CSNK2A1 | |
| SCHEMBL4594776 | 0.79 | PIM1 (0.70) | PIM1PIM3PIM2CDC7CSNK2A1 | |
| SCHEMBL4594347 | 0.79 | PIM1 (1.00) | PIM1PIM3PIM2CDC7CSNK2A1 | |
| SCHEMBL23610610 | 0.77 | KDM4E (0.69) | PIM1PIM3PIM2CDC7CSNK2A1 | |
| SCHEMBL1857738 | 0.75 | KDM4E (1.00) | PIM1PIM3PIM2CDC7CSNK2A1 | |
| SCHEMBL31110304 | 0.75 | KDM4E (0.66) | PIM1PIM3PIM2CDC7CSNK2A1 | |
| SCHEMBL24055232 | 0.75 | KDM4E (0.66) | PIM1PIM3PIM2CDC7CSNK2A1 | |
| SCHEMBL4593656 | 0.74 | ALDH1A1 (0.65) | PIM1PIM3PIM2CDC7CSNK2A1 | |
| SCHEMBL27164741 | 0.73 | KDM4E (0.76) | PIM1PIM3PIM2CDC7CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | CELLZOME (UK) LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | CELLZOME (UK) LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | CELLZOME (UK) LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1945646-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Cellzome (UK) Ltd. (GB) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007039467-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME (UK) LTD. (GB) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039467-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME (UK) LTD. (GB) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | HRH4, HRH3, HRH2 | PIM1 4157/4885PIM3 4362/4885PIM2 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.